Ghana will produce its first locally manufactured vaccine by 2027, Mahama says
President John Dramani Mahama says Ghana will produce its first locally manufactured vaccine by 2027, in a drive for vaccine self-sufficiency built on fill-and-finish manufacturing, the National Vaccine Institute and a stronger Food and Drugs Authority. He said clinical trials are critical to the plan, because locally made vaccines must be tested, proven safe and trusted by Ghanaians. The 2027 date is the president's projection, not an accomplished fact: no product or manufacturer was named in the reporting read.

Key points
- Mahama: Ghana will produce its first locally manufactured vaccine by 2027 — his projection, stated as a national goal.
- First phase is fill-and-finish manufacturing, built on the National Vaccine Institute, with the Food and Drugs Authority's regulation strengthened.
- Clinical trials are critical, the president said: local vaccines must be proven safe and trusted, and he urged Ghanaians to take part in trials.
Show more (1)
- No specific vaccine product or manufacturer was named in the reporting read.
What happened
Ghana set up the National Vaccine Institute after COVID-19 exposed Africa's dependence on imported vaccines. Fill-and-finish — filling and packaging vaccine made from imported bulk — is the usual first step into local production, ahead of making the vaccine substance itself.
What we know / what we don't know yet
What we know
- The president's 2027 goal and the shape of the plan — fill-and-finish first, the National Vaccine Institute, FDA strengthening — from his own remarks as reported by MyJoyOnline.
- His insistence that clinical trials and public trust are central to the plan.
What we don't know yet
- Which vaccine Ghana will produce first, and with which manufacturer — neither was named in the reporting read.
- The production facility's current readiness and the plan's funding — neither was established in the reporting read.
Claim by claim
Show all claims (3)
Why this label: Verified for the fact the president said it and set out that plan, in his own words as reported by MyJoyOnline; the 2027 production itself is a projection, carried as such throughout.
On the ladder: a claim earns Verified from primary evidence, or from two independent sources that do not copy each other.
Why this label: The president's own words on trials and trust, from MyJoyOnline's report of his remarks.
On the ladder: a claim earns Verified from primary evidence, or from two independent sources that do not copy each other.
Why this label: The president's stated reasoning, in his own words as reported.
On the ladder: a claim earns Verified from primary evidence, or from two independent sources that do not copy each other.
Why it matters
A country that cannot make its own vaccines waits in line in a pandemic. Mahama's 2027 date is the first public deadline attached to Ghana's institute — whether a product, a facility and trials are in place to meet it is the test the deadline now sets.
Background
Africa depends on imported vaccines and waits behind producing countries — the experience Mahama cites as the drive's lesson.
Mahama sets 2027 for Ghana's first locally manufactured vaccine and puts clinical trials at the centre of the plan.
Update history
No silent edits. Every change is written here, with its time.
- Latest
Published — the president's statement is confirmed against MyJoyOnline's reports of his remarks; the 2027 date is carried as his projection.